@Mcdivot06 @SeekingAlpha $ARWR $JNJ $AMGN $PFE Good question. A segment of biosimilars are worth the fight risk because the market is so lucrative. This is occurring now w/numerous BP’s. I think it boils down to interloper risk/reward. https://t.co/vNPjSlG0go